WASHINGTON, June 23, 2020 /PRNewswire/ -- The Lung Cancer Registry has launched a landmark new survey on the impact of lung treatments on women's sexual health. The aim is to explore the magnitude of the problem and give researchers and clinicians new insights [...]
A historic milestone was reached today with the exciting announcement that the Department of Veterans Affairs (VA) and GO2 for Lung Cancer (GO2 for Lung Cancer) have established a formal partnership to advance lifesaving screening and care for our [...]
SAN CARLOS, Calif. and WASHINGTON, May 13, 2020 /PRNewswire/ -- GO2 for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, Ph.D., to the role of chief scientific officer. In her new position, Dr. King will be responsible for leading scientific and research priorities for a global [...]
On March 27, 2020, the Food and Drug Administration (FDA) approved Imfinzi (durvalumab) in combination with etoposide and either carboplatin or cisplatin as first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The FDA based their [...]
SAN CARLOS, Calif. and WASHINGTON, Feb. 6, 2020 /PRNewswire/ -- ALK Positive (a patient-led group of 1,900+ lung cancer patients and caregivers in 50+ countries) and GO2 for Lung Cancer (a global lung cancer advocacy and education organization) are awarding a two-year, $500,000 Research Collaboration Grant to two renowned lung [...]
GO2 for Lung Cancer points to targeted treatments and early screenings SAN CARLOS, Calif. and WASHINGTON, Jan. 8, 2020 /PRNewswire/ -- Today's report concerning improvements in cancer mortality is welcomed news. The recently released Cancer Statistics 2020 report shows that the decline in lung cancer deaths [...]
SAN CARLOS, Calif. and WASHINGTON DC, December 12, 2019 – The Lung Cancer Registry has launched new surveys to do an even better job of capturing important moments in a patient’s lung cancer journey. These new surveys include questions [...]
On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no [...]
SAN CARLOS, Calif., Dec. 3, 2019 -- GO2 for Lung Cancer announced the recipients of the 2019 Young Innovators Team Awards (YITA) today. Two teams of researchers received grants totaling $500,000 for their work developing novel strategies to treat KRAS-mutant non-small cell lung cancer (NSCLC) [...]
AstraZeneca Announced as 2019 "Simply the Best Award" Honoree SAN CARLOS, Calif. and WASHINGTON DC, November 12, 2019 – GO2 for Lung Cancer (a merger of the Bonnie J. Addario Lung Cancer Foundation and Lung Cancer Alliance) recognized AstraZeneca [...]